Clopidogrel (clopidogrel bisulfate) NDC 70518-4373

NDC codes

FDA NDC Directory

Product NDC (as listed)70518-4373Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70518-4373Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70518-4373-0	70518437300	90 TABLET in 1 BOTTLE, PLASTIC (70518-4373-0)Marketed from Jun 26, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Clopidogrel
Generic name (nonproprietary): clopidogrel bisulfate
Active ingredients: Clopidogrel bisulfate — 75 mg/1
Dosage form: Tablet
Route: Oral
Labeler: REMEDYREPACK INC.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 203632
Marketing start: Jun 26, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2C8 Inhibitors (Mechanism)Decreased Platelet Aggregation (Physiologic effect)P2Y12 Receptor Antagonists (Mechanism)
Identifiers: Product ID 70518-4373_5b0d7f5a-e02a-62bb-e063-6294a90a8df5SPL ID 5b0d7f5a-e02a-62bb-e063-6294a90a8df5SPL set ID 669f0bc6-f173-484d-8efe-c006683b25d1RxCUI 309362UNII 08I79HTP27
Pharmacologic class: P2Y12 Platelet Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470518437300 followed by a unit qualifier and the quantity

Package 70518-4373-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 9, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Clopidogrel tablets is a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS(unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel tablets is indicated to reduce the rate …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 203632

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 203632
Product	Strength	Form · route	Labeler	Product NDC
Clopidogrelclopidogrel bisulfate	Clopidogrel bisulfate 75 mg/1	TabletOral	A-S Medication Solutions	50090-7466
Clopidogrelclopidogrel bisulfate	Clopidogrel bisulfate 75 mg/1	TabletOral	A-S Medication Solutions	50090-7467
Clopidogrelclopidogrel bisulfate	Clopidogrel bisulfate 75 mg/1	TabletOral	Ascend Laboratories, LLC	67877-276